This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview

This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

Expanding Strategies and Therapeutic Options for Treating-To-Target in Rheumatoid Arthritis

Expanding Strategies and Therapeutic Options for Treating-To-Target in Rheumatoid Arthritis

Format

Patient Case Study

Time to Complete

30 minutes

Released

May 8, 2018

Expires

May 7, 2019
Add to Queue


Maximum Credits

0.50 / AMA PRA Category 1 CreditTM
0.50 / CNE Contact Hours (0.50 pharmacology credit)
0.50 / CE for Pharmacists

Accredited Provider



Provided by Boston University School of Medicine (BUSM)

Commercial Supporter

This activity is supported by an independent educational grant from Pfizer Inc.

Program Description

In the current rheumatoid arthritis (RA) treatment landscape, there are many treatment options available, but as RA is a chronic disease, many patients may not always respond adequately or fully to their initial or ongoing treatments. Choosing appropriate treatment remains a challenge, particularly in cases of inadequate understanding of various treatment profiles and recommendations along with an ongoing lack of expert consensus. Over the past few years, comparative effectiveness trials and treat-to-target approaches have become essential needs in RA in order to deliver the most appropriate care on an individualized basis. It is imperative that healthcare professionals understand these unmet needs, and how overcoming them can favorably affect treatment decisions and patient outcomes.

Intended Audience

This activity will target key members of the rheumatology care team including: rheumatologists, nurse practitioners, physician assistants, nurses and pharmacists who care for patients with RA.

Educational Objectives

After completing this activity, the participant will be better able to:

  • Review the guidelines and clinical benefits/drawbacks of monotherapy for RA, in comparison to combination therapy.
  • Evaluate the applicability of treating-to-target in rheumatoid arthritis and define ways in which to implement this approach in practice.

Conflict Of Interest Disclosure Policy

Boston University School of Medicine asks all individuals involved in the development and presentation of Continuing Medical Education (CME) activities to disclose all relevant relationships with commercial interests. This information is disclosed to CME activity participants. Boston University School of Medicine has procedures to resolve all relevant conflicts of interest. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.

Faculty

Tuhina Neogi, MD, PhD
CME Course Director
Professor of Medicine
Boston University School of Medicine
Boston, MA

Dr. Neogi is a consultant for Pfizer and for Novartis.

Jon T. Giles, MD, MPH
Associate Professor of Medicine
Division of Rheumatology
Columbia University, Vagelos College of Physicians and Surgeons
New York, NY

Dr. Giles receives grant support from Pfizer. He is a consultant for Genentech and for Lilly.

Naomi Amudala, RN, FNP-BC
CNE Course Advisor
Assistant Professor of Medicine
Vasculitis Center/Rheumatology
Boston University School of Medicine
Boston, MA

Ms. Amudala has no relevant financial relationships to disclose.

Jinoos Yazdany, MD, MPH
Robert L. Kroc Endowed Chair in Rheumatic and Connective Tissue Diseases
Associate Professor in the Division of Rheumatology
Co-Director UCSF Lupus Clinic
University of California, San Francisco (UCSF)
San Francisco, CA

Dr. Yazdany is a research consultant for Astra Zeneca and recipient of an Independent Investigator Award from Pfizer.

Accredited Provider Disclosure

Independent Reviewer: Jason Worcester, MD, Boston University School of Medicine
Medical Writer/Editor: Christopher Drury, MA, The Quill Consulting, LLC, Norfolk, MA

Planning Committee Disclosures

Jason Worcester, MD, Jody Walker, MS, Dana Frazier, CHCP, BBA, Carmela A. Townsend, DNP, MS/MBA, RN, Lead Nurse Planner, of Boston University School of Medicine and Christopher Drury, MA, of The Quill Consulting, LLC., have no relevant relationships to disclose.

Credit

0.50

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement

Boston University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation Statement

Boston University School of Medicine designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)TM  . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit

0.50

Type

CNE Contact Hour(s)

Accreditation Statement

Continuing Nursing Education Provider Unit, Boston University School of Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Designation Statement

This enduring material designates 0.50 Contact Hours, all of which are eligible for pharmacology credit.

Credit

0.50

Type

CE for Pharmacists

Accreditation Statement

The University of Rhode Island College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Designation Statement

This is a knowledge-based educational activity. Pharmacists will receive 0.50 Contact Hour (0.05 CEU) for each educational activity.

Universal Activity Number (UAN): 0060-9999-18-026-H01-P

Disclosure of Unlabeled Use

The faculty members do not plan on discussing unlabeled/investigational uses of a commercial product.

Disclaimer

THIS CONTINUING MEDICAL EDUCATION PROGRAM IS INTENDED SOLELY FOR EDUCATIONAL PURPOSES FOR QUALIFIED HEALTH CARE PROFESSIONALS. IN NO EVENT SHALL BOSTON UNIVERSITY BE LIABLE FOR ANY DECISION MADE OR ACTION TAKEN IN RELIANCE ON THE INFORMATION CONTAINED IN THE PROGRAM. IN NO EVENT SHOULD THE INFORMATION CONTAINED IN THE PROGRAM BE USED AS A SUBSTITUTE FOR PROFESSIONAL CARE. NO PHYSICIAN-PATIENT RELATIONSHIP IS BEING ESTABLISHED.

Instructions

HOW TO RECEIVE ACCME/ANCC CREDIT
In order to successfully complete this activity, you are required to read the entire online module, answer all questions within the module, and then complete the posttest and evaluation. CME/CNE credits will be awarded provided a score of 70% or better is achieved. A certificate of credit is available for immediate download to those who successfully complete the examination, and answer the evaluation questions.

HOW TO RECEIVE ACPE CREDIT
In order to successfully complete this activity, participants are required to read the entire online module, answer all questions within the module, and then complete the posttest and evaluation. CE credits will be awarded provided a score of 70% or better is achieved. Another program evaluation must be completed at www.uripharmacycpd.org within 60 days of the program completion date in order to receive CE credit. CE credit will be transferred to the CPE Monitor upon successful completion of the program evaluation. Transfer of CE credit should be verified at mycpemonitor.net where CE statements are available to print. Please refer to the evaluation instructions that follow for completing program evaluations and reporting CE credit.

For questions about CME, please contact cme@bu.edu or www.bu.edu/cme.
Add to Queue


Related to this activity